Human anti-pneumococcal polysaccharide antibodies are secreted by the CD5− B cell lineage

Barrett, Douglas J.; Sleasman, John W.; Schatz, Desmond

doi:10.1016/0008-8749(92)90006-b

Cited by 19 publications

(12 citation statements)

References 64 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our data therefore confirm previous suggestions that there may be an association between CD19 ϩ CD5 ϩ B cell predominance and specific antipolysaccharide deficiency (10) and that human IgG caps-PS-secreting cells bear the CD19 ϩ CD5 Ϫ phenotype (8). Serotype-dependent differences, however, may exist.…”

Section: Cd5supporting

confidence: 91%

“…Interestingly, enzyme-linked immunosorbent spot (ELISpot) analysis of isolated cell populations revealed that the CD5 Ϫ subset of these cells had a higher capacity than the CD5 ϩ subset for the production caps-PS-specific antibodies (particularly IgG) (8). This finding (8) is in line with data from an older study by Barrett et al, who found that anti-type 4 pneumococcal polysaccharide antibody-secreting cells were found in the CD5 Ϫ B cell subpopulation (10). Furthermore, the importance of the CD5 Ϫ subset of B cells for antibody production in response to polysaccharide antigens is also suggested by peripheral blood CD5 ϩ B cell predominance in patients with a specific antipolysaccharide antibody deficiency (11).…”

supporting

confidence: 76%

“…Serotype 4 was selected, as this serotype was previously used for ELISpot analysis (8,10). Although there was a substantial variation in the number of antibody-secreting cells among the five individuals (summarized in Table 1), the number of IgG antibody-secreting cells consistently tended to be higher in the CD19 ϩ CD5 Ϫ cell subset than in the CD19 ϩ CD5 ϩ cell subset (P ϭ 0.06 by Wilcoxon test).…”

Section: Resultsmentioning

confidence: 99%

See 2 more Smart Citations

Anti-Pneumococcal Capsular Polysaccharide Antibody Response and CD5 B Lymphocyte Subsets

et al. 2015

View full text Add to dashboard Cite

Section: Cd5supporting

confidence: 91%

supporting

confidence: 76%

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

Anti-Pneumococcal Capsular Polysaccharide Antibody Response and CD5 B Lymphocyte Subsets

et al. 2015

View full text Add to dashboard Cite

“…Theoretically, inducing immunologic memory would allow an anamnestic response to revaccination, providing longer, more durable protection against infection. Conjugate vaccines have been shown to improve pneumococcal vaccine responses in children, who typically have poor responses to PPV attributable to delayed maturation of subsets of B cells (10,114).…”

Section: Pcvmentioning

confidence: 99%

Pneumococcal Vaccination and Revaccination of Older Adults

2003

View full text Add to dashboard Cite

As individuals advance in age, the risk of infection, bacteremia, and mortality caused by Streptococcus pneumoniae rises. Retrospective data demonstrate that the licensed penumococcal polysaccharide vaccine (PPV) is effective in older persons in reducing serotype-specific invasive disease. PPV demonstrates good immunogenicity in older adults, generally comparable to that in younger subjects, although certain cohorts respond less well. The response to PPV is T cell independent, however, and does not elicit immunologic memory. The duration of the anti-capsular polysaccharide antibody response appears to wane as early as 3 years after vaccination. In older persons, revaccination induces an antibody response, although it may not be as strong as that from the initial vaccine. While revaccination of older adults has been recommended, clinical efficacy has not yet been proven. Measures of antibody function may be at least as important in determining protection as are quantitative antibody levels. Additional studies of immunogenicity, particularly regarding revaccination, will facilitate the design of an optimal pneumococcal vaccination policy. Research into conjugate- and protein-based pneumococcal vaccines, which elicit T-cell-dependent responses and induce immunologic memory, is needed in older persons. In the meantime, administering to PPV to recommended groups should be a public health priority

show abstract

“…Streptococcus pneumoniae is the causal agent in more than one third of bacterial pneumonias in these children (4,13). Young children are at high risk because of their naïve immune system and the reduced ability to mount an antipolysaccharide immune response (3,10). The pneumococci reside in the nasopharynx, usually without causing disease, but may spread locally and cause otitis media, sinusitis, and lower respiratory tract infections and can reach the bloodstream to cause meningitis, infection in other organs, and sepsis.…”

mentioning

confidence: 99%

Effects of Zinc Deficiency and Pneumococcal Surface Protein A Immunization on Zinc Status and the Risk of Severe Infection in Mice

et al. 2003

View full text Add to dashboard Cite

Streptococcus pneumoniae is a major cause of illness and death in children in developing countries. In these children, zinc deficiency is associated with an increased risk of acute respiratory tract infections, which can be reduced by daily zinc administration. Severe infections decrease zinc levels in plasma and may thereby move individuals with preexisting low zinc stores into a vicious cycle of infection and unavailable zinc. Pneumococcal surface protein A (PspA) has emerged as a promising vaccine candidate, and immunization with this antigen protects animals from pneumococcal infection. In an animal experiment, we measured the effect of zinc depletion on the immune response to parenterally administrated PspA and assessed the effect of this PspA vaccination and zinc depletion on the severity of pneumococcal infection and on zinc status. Mice were kept on different diets for 5 weeks, immunized twice 14 days apart, and challenged intranasally with S. pneumoniae. Mice on the zinc-deficient diet showed substantially reduced immune responses to PspA, more extensive pneumococcal colonization in the nasal mucosa, more severe infections, and an increased risk of death. PspA immunization reduced the risk of severe disease, and the reduction in severity was reflected in substantially reduced zinc depletion from bones.

show abstract

Human anti-pneumococcal polysaccharide antibodies are secreted by the CD5− B cell lineage

Cited by 19 publications

References 64 publications

Anti-Pneumococcal Capsular Polysaccharide Antibody Response and CD5 B Lymphocyte Subsets

Anti-Pneumococcal Capsular Polysaccharide Antibody Response and CD5 B Lymphocyte Subsets

Pneumococcal Vaccination and Revaccination of Older Adults

Effects of Zinc Deficiency and Pneumococcal Surface Protein A Immunization on Zinc Status and the Risk of Severe Infection in Mice

Contact Info

Product

Resources

About